Contract drug manufacturing (CDMO) stocks
CDMO
What are Contract drug manufacturing (CDMO) stocks in Korea?
The Contract drug manufacturing (CDMO) theme on jonbur groups 26 Korean stocks listed on KOSPI and KOSDAQ, worth ₩135T in total. On Oct 30, 2026 the group moved up 5.01% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Hanmi Pharm.
Key facts
- Stocks
- 26
- Total market value
- ₩135T
- Day's move
- +5.01%
- As of
- Oct 30, 2026
- Largest members
- Samsung Biologics, Celltrion, Hanmi Pharm
Earnings tracker · 1Q 2026
Past quarter
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Samsung Biologics | May 15 | ₩1.3T | −3.2% | ₩581B | +19.3% | +53.6% | 46.2%37.5% |
| Celltrion | May 15 | ₩1.1T | +36.0% | ₩322B | +115.4% | −32.3% | 28.1%17.7% |
| Hanmi Pharm | May 15 | ₩393B | +0.5% | ₩54B | −9.1% | −35.6% | 13.7%15.1% |
| SAM Chun Dang Pharm | May 15 | ₩65B | +28.2% | ₩5.4B | +692.4% | +0.4% | 8.4%1.4% |
| SK Bioscience | May 13 | ₩169B | +9.1% | −₩45B | Bigger loss | Smaller loss | −26.4%−9.8% |
| GC Biopharma | May 15 | ₩436B | +13.5% | ₩12B | +47.3% | +154.9% | 2.7%2.1% |
| ST Pharm | May 15 | ₩67B | +27.7% | ₩12B | +1,024.6% | −56.1% | 17.2%2.0% |
| Daewoong Pharma | May 15 | ₩378B | +6.0% | ₩22B | −42.6% | −48.8% | 5.9%10.9% |
| Chong Kun Dang Pharmaceutical | May 15 | ₩448B | +11.7% | ₩14B | +13.1% | −40.0% | 3.1%3.1% |
| L&C Bio | May 15 | ₩30B | +70.6% | ₩6B | Turned to profit | +206.9% | 19.8%−2.4% |
| Chabiotech | May 15 | ₩330B | +8.4% | −₩31B | Bigger loss | Bigger loss | −9.3%−4.1% |
| Proteina | May 15 | ₩169M | — | −₩4.7B | — | Bigger loss | −2,795.5% |
| Samyang Holdings | May 15 | ₩838B | −3.2% | ₩29B | −7.4% | Turned to profit | 3.5%3.6% |
| IL Dong Pharmaceutical | May 15 | ₩142B | +4.4% | ₩9.2B | +120.0% | +16.4% | 6.5%3.1% |
| Dong-A ST | May 15 | ₩204B | +11.8% | ₩7.8B | Turned to profit | Turned to profit | 3.8%−2.6% |
| Medipostco | May 15 | ₩19B | +1.2% | −₩17B | Bigger loss | Smaller loss | −86.6%−71.1% |
| Inventage Lab | Jun 1 | ₩393M | +132.3% | −₩8.4B | Bigger loss | Bigger loss | −2,135.2%−3,178.1% |
| EuBiologics | May 14 | ₩16B | −60.4% | ₩2.2B | −87.0% | −83.9% | 14.0%42.8% |
| Huons | May 15 | ₩142B | −2.7% | −₩649M | Turned to loss | Turned to loss | −0.5%8.8% |
| Binex | May 15 | ₩35B | −11.2% | −₩9B | Turned to loss | Bigger loss | −25.4%1.4% |
| IMBiologics | May 14 | ₩7.2B | — | ₩2.7B | — | — | 37.8% |
| Kolon Life Science | — | ₩50B | +10.8% | ₩2.9B | +3,839.0% | Turned to profit | 5.9%0.2% |
| BNC Korea | May 15 | ₩21B | −18.4% | −₩1.5B | Turned to loss | Smaller loss | −7.1%14.9% |
| SeouLin Bioscience | May 15 | ₩20B | +8.3% | ₩175M | +79.8% | +22.7% | 0.9%0.5% |
| LabGenomics | May 15 | ₩18B | −18.1% | −₩4.2B | Smaller loss | Smaller loss | −23.3%−26.1% |
| Dt&Cro | May 15 | ₩10B | +0.2% | −₩3.6B | Bigger loss | Turned to loss | −35.4%−34.5% |
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 30, 2026- Above 20-day average
- 15.4%
- Above 60-day average
- 19.2%
- RSI above 70
- 0%
- RSI below 30
- 15.4%
- 52-week highs
- 0
- 52-week lows
- 6
Index gauge · Short term
Bearish
1 bullish, 1 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The contract drug manufacturing (CDMO) theme covers 26 members, and only 15.4% of them trade above their 20-day average while 19.2% sit above their 60-day average. No member is currently recording a 52-week high, while 6 are at 52-week lows, and 15.4% of members have an RSI in the oversold zone with none in the overbought zone. The equal-weighted index gauge reads bearish on both the short and medium horizons, with RSI at 39 and the index trading below its cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
- MaturitiesOct 20, 202685SK Reit: ₩130bn of bonds due in the next 6 months vs ₩54bn cash₩350bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2025 FY.SK ReitSK hynixSK NetworksSK DiscoverySKCSK Telecom
Creators talking about this
Contract drug manufacturing (CDMO)
−0.47%CDMO
The CDMO (contract development and manufacturing organization) theme covers Korean companies that develop and manufacture pharmaceuticals, biologics, and related products on behalf of other drug companies, rather than selling their own branded medicines. Korean investors often group these firms together because they share a business model centered on large-scale bioproduction capacity, long-term client contracts, and exposure to the global biopharma outsourcing trend. The theme is also frequently linked to the broader Korean biotech sector, so its share prices tend to move alongside related names.
26 companies · 8 up · 0 flat · 18 down
- Traded value
- ₩414B
- Value vs 20-day average
- 1.14×
- Top gainer
- Samsung Biologics +8.86%
- Largest company
- Samsung Biologics ₩69T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,487,000 | +8.86% | ₩144B | ₩69T | 6.88% |
Celltrion068270 · KOSPI | ₩191,600 | +1.22% | ₩100B | ₩44T | 7.28% |
Hanmi Pharm128940 · KOSPI | ₩415,000 | +6.82% | ₩103B | ₩5.3T | 9.61% |
SAM Chun Dang Pharm000250 · KOSDAQ | ₩182,700 | −3.13% | ₩15B | ₩4.3T | 1.34% |
SK Bioscience302440 · KOSPI | ₩32,750 | +1.71% | ₩2.9B | ₩2.6T | 5.50% |
GC Biopharma006280 · KOSPI | ₩130,200 | −1.36% | ₩3.2B | ₩1.5T | 6.68% |
ST Pharm237690 · KOSDAQ | ₩72,500 | −2.03% | ₩8.5B | ₩1.5T | 5.77% |
Daewoong Pharma069620 · KOSPI | ₩101,100 | −0.39% | ₩3.1B | ₩1.2T | 10.30% |
Chong Kun Dang Pharmaceutical185750 · KOSPI | ₩63,100 | +0.96% | ₩1.5B | ₩871B | 6.34% |
L&C Bio290650 · KOSDAQ | ₩23,950 | −4.58% | ₩5.5B | ₩646B | 1.28% |
Chabiotech085660 · KOSDAQ | ₩6,750 | −0.15% | ₩1B | ₩628B | 0.31% |
Proteina468530 · KOSDAQ | ₩54,300 | +0.74% | ₩13B | ₩603B | 3.78% |
Samyang Holdings000070 · KOSPI | ₩52,300 | −0.38% | ₩338M | ₩406B | 2.68% |
IL Dong Pharmaceutical249420 · KOSPI | ₩12,580 | +0.08% | ₩6.7B | ₩398B | 2.30% |
Dong-A ST170900 · KOSPI | ₩33,850 | −0.44% | ₩502M | ₩329B | 4.78% |
Medipostco078160 · KOSDAQ | ₩8,090 | −3.11% | ₩485M | ₩317B | 1.55% |
Inventage Lab389470 · KOSDAQ | ₩22,100 | −3.91% | ₩1.1B | ₩294B | 0.31% |
EuBiologics206650 · KOSDAQ | ₩7,730 | −0.90% | ₩598M | ₩281B | 0.17% |
Huons243070 · KOSDAQ | ₩16,960 | −0.41% | ₩449M | ₩203B | 0.71% |
Binex053030 · KOSDAQ | ₩6,030 | −0.82% | ₩446M | ₩197B | 2.17% |
IMBiologics493280 · KOSDAQ | ₩13,160 | −4.64% | ₩1.6B | ₩195B | — |
Kolon Life Science102940 · KOSDAQ | ₩12,410 | −3.27% | ₩784M | ₩162B | 0.50% |
BNC Korea256840 · KOSDAQ | ₩2,350 | −3.29% | ₩1B | ₩161B | — |
SeouLin Bioscience038070 · KOSDAQ | ₩3,565 | −1.11% | ₩26M | ₩33B | — |
LabGenomics084650 · KOSDAQ | ₩2,095 | +4.23% | ₩94M | ₩31B | 0.58% |
Dt&Cro383930 · KOSDAQ | ₩1,836 | −2.91% | ₩34M | ₩23B | — |
Source: KRX statistical information